Dr. Richard L. Deming
Claim this profileMercy Medical Center - Des Moines
Expert in Cancer
Expert in Lung Cancer
177 reported clinical trials
241 drugs studied
About Richard L. Deming
Education:
- Obtained MD from Creighton University School of Medicine in 1980.
- Completed Residency in Radiation Oncology at the University of California, San Francisco.
Experience:
- Internship at Naval Medical Center in 1981.
- Served as Medical Director of Mercy Cancer Center and Chairman of the Oncology Service Line at Mercy Medical Center.
- Founder and Chairman of Above + Beyond Cancer, a nonprofit organization.
- Recipient of the Lane Adams Quality of Life Award and the St. George National Award.
- Affiliated with Mercyone Des Moines Medical Center, boasting over 43 years of experience in Radiation Oncology.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Richard L. Deming is currently running
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Trastuzumab Emtansine
for Salivary Gland Cancer
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab emtansine may work better compared to usual treatment of chemotherapy with docetaxel and trastuzumab in treating patients with salivary gland cancer.
Recruiting1 award Phase 2
More about Richard L. Deming
Clinical Trial Related4 years of experience running clinical trials · Led 177 trials as a Principal Investigator · 100 Active Clinical TrialsTreatments Richard L. Deming has experience with
- Nivolumab
- Carboplatin
- Cisplatin
- Atezolizumab
- Paclitaxel
- Pembrolizumab
Breakdown of trials Richard L. Deming has run
Cancer
Lung Cancer
Breast Cancer
Relapse
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Richard L. Deming specialize in?
Richard L. Deming focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Richard L. Deming currently recruiting for clinical trials?
Yes, Richard L. Deming is currently recruiting for 96 clinical trials in Des Moines Iowa. If you're interested in participating, you should apply.
Are there any treatments that Richard L. Deming has studied deeply?
Yes, Richard L. Deming has studied treatments such as Nivolumab, Carboplatin, Cisplatin.
What is the best way to schedule an appointment with Richard L. Deming?
Apply for one of the trials that Richard L. Deming is conducting.
What is the office address of Richard L. Deming?
The office of Richard L. Deming is located at: Mercy Medical Center - Des Moines, Des Moines, Iowa 50314 United States. This is the address for their practice at the Mercy Medical Center - Des Moines.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.